Newcastle Disease

You can count a Phase III program at Checkpoint Therapeutics as the latest collateral damage from Russia’s invasion of Ukraine. The biotech $CKPT reported this morning that it has had to scrap the late-stage CONTERNO trial combining cosibelimab with pemetrexed and platinum chemotherapy for non-squamous non-small cell lung cancer after the conflict slowed enrollment for the study. According to Checkpoint: — John Carroll Terns Pharmaceuticals is lining up $65 million to help fund clinical trials across cancer, obesity and the difficult-to-crack NASH. The offering, led by new investors Fairmount and Venrock Healthcare Capital Partners, sent the biotech’s shares $TERN soaring nearly 25% after Friday’s opening bell. The offering is slated to close Tuesday. The Foster City, CA biotech reported earlier this week it had $140 million to keep the lights on into 2025, and with the added boost from the offering, Terns expects to have the cash needed to test a slate of drugs. A Phase I trial of TERN-701 for chronic myeloid leukemia kicked off in China in May, and the new cash haul will fund one or more trials in the US and/or Europe and get it into mid-stage testing. The proceeds will also get TERN-601 into a Phase II study in obesity and provide the money needed to complete the ongoing Phase IIa DUET trial in NASH. That study, testing TERN-501 alone and in combination with ex-Eli Lilly asset TERN-101 , will read out in the second half of next year. — Kyle LaHucik While there are more than a few companies working on vaccines, a new startup out of Mount Sinai is focusing its vaccine efforts on pandemic concerns. The famed hospital system launched the biotech, CastleVax, earlier this week in New York with a few key goals in mind, the first being commercially developing a Newcastle disease virus-based vaccine platform, originally developed in labs at Mount Sinai. Beyond that, the biotech has been working on multiple candidates ranging from preclinical all the way to Phase I and II, and the biotech’s lead candidate (NDV-HXP-S) is for Covid-19. Other viruses the biotech is working on include RSV, HMPV, hepatitis B and C, Lassa virus and Ebola. According to CastleVax, the biotech is looking at engineering NDV to express certain antigenic proteins native to infectious viruses, citing the spike protein in SARS-CoV-2 as an example. The NDV platform could do away with the specialized refrigeration that many current vaccines require, the biotech said. The goal is to research and develop vaccine against what Mount Sinai called “current and potential future pandemic threats,” on top of diseases with unmet need. CEO and president Matt Stober, a former Big Pharma vet who was also the former CEO at Istari Oncology, elaborated on development of the biotech’s Covid-19 candidate, which had already completed Phase I and II clinical trials. “We aim to engineer vaccines to fight a broad range of future respiratory pandemic threats that experts in the field foresee as inevitable,” Stober added. — Paul Schloesser

Reports Revenue of $2.1 Billion, Growing 5%, and Net Income of $529 Million, or $1.12 per Diluted Share, Increasing 3% and 5%, Respectively, on a Reported Basis for Second Quarter 2022 Delivers 8% Operational Growth in Revenue and 9% Operational Growth in Adjusted Net Income for Second Quarter 2022 Reports Adjusted Net Income of $567 Million, or Adjusted Diluted EPS of $1.20, for Second Quarter 2022 Updates Full Year 2022 Revenue Guidance to $8.225 - $8.325 Billion, with Diluted EPS of $4.65 to $4.75 on a Reported Basis, or $4.97 to $5.05 on an Adjusted Basis PARSIPPANY, N.J.--(BUSINESS WIRE)-- Zoetis Inc. (NYSE: ZTS) today reported its financial results for the second quarter of 2022 and updated its guidance for full year 2022 to reflect its positive outlook for the remainder of the year, as well as the negative impact of recent changes to foreign exchange rates. The company reported revenue of $2.1 billion for the second quarter of 2022, an increase of 5% compared with the second quarter of 2021. Net income for the second quarter of 2022 was $529 million, or $1.12 per diluted share, an increase of 3% and 5%, respectively, on a reported basis. On an operational1 basis, revenue for the second quarter of 2022 increased 8%, excluding the impact of foreign currency. Adjusted net income for the second quarter of 2022 increased 9% operationally, excluding the impact of foreign currency. Adjusted net income2 for the second quarter of 2022 was $567 million, or $1.20 per diluted share, which was flat and an increase of 1%, respectively, on a reported basis. Adjusted net income for the second quarter of 2022 excludes the net impact of $38 million for purchase accounting adjustments, acquisition-related costs and certain significant items. EXECUTIVE COMMENTARY “Zoetis delivered another strong quarter, with 8% operational revenue growth and 9% operational growth in adjusted net income, driven once again by the strength of our companion animal portfolio,” said Zoetis Chief Executive Officer Kristin Peck. “Our diversity and strength across parasiticides, dermatology products, vaccines and monoclonal antibodies for pain continue to demonstrate people’s desire for innovative and effective care for their pets." “Our business remains strong thanks to the durability of our global portfolio and a steady pipeline of new products. Even as we face uncertain macroeconomic conditions, continued supply constraints, generic competition and the war in Ukraine, we remain confident in the resilience of our business and colleagues. As we look at the rest of the year, we are updating and narrowing our guidance to reflect our positive outlook for the remainder of the year, as well as recent changes to foreign exchange rates." QUARTERLY HIGHLIGHTS Zoetis organizes and manages its commercial operations across two segments: United States (U.S.) and International. Within these segments, the company delivers a diverse portfolio of products for companion animals and livestock, tailored to local trends and customer needs. In the second quarter of 2022: Revenue in the U.S. segment was $1.091 billion, an increase of 9% compared with the second quarter of 2021. Sales of companion animal products increased 13%, driven by growth across the company’s parasiticide portfolio, primarily Simparica Trio® for dogs. The company's dermatology portfolio also contributed to growth across both the Apoquel® and Cytopoint® brands. Sales of livestock products declined 7% in the quarter. Sales of cattle products declined as a result of generic competition for Draxxin® and continued weakness in beef and dairy markets. The company’s poultry portfolio declined due to the expanded use of lower cost alternatives and generic competition for Zoamix®, the company’s alternative to antibiotics in medicated feed additives. Sales of swine products grew primarily from higher disease prevalence and favorable market conditions for producers. Revenue in the International segment was $943 million, an increase of 2% on a reported basis and an increase of 8% operationally compared with the second quarter of 2021. Growth across species was impacted by lower sales due to the war in Ukraine. Sales of companion animal products grew 8% on a reported basis and 16% operationally. Growth resulted from increased sales of the company’s recently launched monoclonal antibody (mAb) products for osteoarthritis pain, Librela® and Solensia®, as well as the key dermatology portfolio across both the Apoquel and Cytopoint brands. The Simparica® portfolio, including Simparica Trio, also contributed to growth in the quarter. Sales of livestock products declined 3% on a reported basis and grew 2% operationally. Growth in the company’s fish portfolio was primarily the result of increased sales of vaccines across key salmon markets, including Chile and Norway. Sales of cattle products grew due to favorable market conditions and price in key and emerging markets, including Australia, Turkey, China and the U.K. Sales of sheep products grew as a result of favorable market conditions and new product launches in Australia. Sales of swine products decreased in the quarter due to lower pork prices and COVID-related lockdowns in China, which temporarily impacted the company’s supply chain in the market, as well as an exceptionally strong comparative period versus the second quarter of last year. The poultry products portfolio declined due to the unfavorable impact of producer rotational programs with certain medicated feed additives in Europe and reduced flock sizes in Latin American markets. INVESTMENTS IN GROWTH AND SUSTAINABILITY Zoetis continues to gain market approvals and introduce lifecycle innovations for key brands. On the companion animal side of the business, the company received approval in Mexico and New Zealand for Apoquel Chewable Tablets. Previously approved in the EU and the U.K., the new chewable version of Apoquel (oclacitinib) provides veterinarians and pet owners with a convenient solution to quickly and safely stop the cycle of pruritus in allergic dogs and clinical signs of atopic dermatitis in dogs. In parasiticides, a new label indication for Simparica Trio (sarolaner/moxidectin/pyrantel chewable tablets) was approved in Canada. The label expansion now includes the reduction of infections that may cause Lyme disease in dogs by killing deer ticks, also called black-legged ticks, as well as approval for the treatment and control of certain hookworms. On the livestock side of the business, Zoetis expanded its poultry vaccine portfolio in the U.S. with the approval of Poulvac® Procerta® HVT-IBD-ND, an advanced trivalent vector vaccine that delivers powerful early protection against Marek’s disease, infectious bursal disease and Newcastle disease in one dose. This is the third recombinant vector vaccine from Zoetis, following the introduction of Poulvac® Procerta® HVT-ND in 2020 and Poulvac® Procerta® HVT-IBD in 2021. In Business Development news, Zoetis acquired Basepaws, a privately held petcare genetics company, in June. Basepaws provides pet owners with genetic tests, analytics and early health risk assessments, which help pet owners and veterinarians understand an individual pet’s risk for disease and can lead to more meaningful engagements and increased likelihood of early detection and treatment of disease. The acquisition of Basepaws enhances the company’s portfolio in the precision animal health space and will help inform its future pipeline of petcare innovations. In terms of Sustainability, Zoetis continues to advance its Driven To Care goals that were established last year. In June, the company published its 2021 Progress Update and Environmental, Social and Governance (ESG) metrics, highlighting achievements toward the company’s Diversity, Equity & Inclusion (DE&I) aspirations, expanded climate goals and support for the veterinary profession – underscoring its commitment to be the most sustainable animal health company in the world. FINANCIAL GUIDANCE Zoetis is updating its full year 2022 guidance due to the positive outlook for the remainder of the year, as well as the negative impact of recent changes to foreign exchange rates. This includes: Revenue between $8.225 billion to $8.325 billion Reported diluted EPS between $4.65 to $4.75 Adjusted diluted EPS between $4.97 to $5.05 This guidance reflects foreign exchange rates as of late July. Additional details on guidance are included in the financial tables and will be discussed on the company's conference call this morning. WEBCAST & CONFERENCE CALL DETAILS Zoetis will host a webcast and conference call at 8:30 a.m. (ET) today, during which company executives will review second quarter 2022 results, discuss financial guidance and respond to questions from financial analysts. Investors and the public may access the live webcast by visiting the Zoetis website at . A replay of the webcast will be archived and made available on August 4, 2022. About Zoetis As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After 70 years innovating ways to predict, prevent, detect, and treat animal illness, Zoetis continues to stand by those raising and caring for animals worldwide -- from livestock farmers to veterinarians and pet owners. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $7.8 billion in 2021 with approximately 12,100 employees. For more information, visit . 1 Operational growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange. 2 Adjusted net income and its components and adjusted diluted earnings per share (non-GAAP financial measures) are defined as reported net income and reported diluted earnings per share, excluding purchase accounting adjustments, acquisition-related costs and certain significant items. DISCLOSURE NOTICES Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, future operating or financial performance, future guidance, future operating models; disruptions in our global supply chain; R&D costs; timing and likelihood of success; expectations regarding products, product approvals or products under development, expected timing of product launches; the impact of the coronavirus (COVID-19) global pandemic and any recovery therefrom on our business, supply chain, customers and employees; expectations regarding the performance of acquired companies and our ability to integrate new businesses; expectations regarding the financial impact of acquisitions; future use of cash, dividend payments and share repurchases; tax rate and tax regimes and any changes thereto; and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. Such risks and uncertainties may be amplified by the COVID-19 global pandemic and its potential impact on the global economy and our business. These filings and subsequent filings are available online at , , or on request from Zoetis. Use of Non-GAAP Financial Measures: We use non-GAAP financial measures, such as adjusted net income, adjusted diluted earnings per share and operational results (which exclude the impact of foreign exchange), to assess and analyze our results and trends and to make financial and operational decisions. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this press release should not be considered alternatives to measurements required by GAAP, such as net income, operating income, and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliations of non-GAAP financial measures and the most directly comparable GAAP financial measures are included in the tables accompanying this press release and are posted on our website at . Internet Posting of Information: We routinely post information that may be important to investors in the 'Investors' section of our website at , on our Facebook page at and on Twitter@zoetis. We encourage investors and potential investors to consult our website regularly and to follow us on Facebook and Twitter for important information about us. ZTS-COR ZTS-IR ZTS-FIN View source version on businesswire.com: Contacts Media Contacts: Bill Price 1-973-443-2742 (o) william.price@zoetis.com Kristen Seely 1-973-443-2777 (o) kristen.seely@zoetis.com Investor Contact: Steve Frank 1-973-822-7141 (o) steve.frank@zoetis.com Source: Zoetis Inc. View this news release online at:

NEW YORK, July 1, 2022 /PRNewswire/ -- The "Animal Disinfectant Market by Type (liquid animal disinfectant and powdered animal disinfectant) and Geography (Europe, North America, Asia, and ROW) - Forecast and Analysis 2021-2025" report has been added to Technavio's offering. With ISO 9001:2015 certification, Technavio is proudly partnering with more than 100 Fortune 500 companies for over 16 years. The animal disinfectant market size is expected to increase by USD 1.17 million from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 6.75%. 42% of the market's growth will originate from Asia during the forecast period. China is the key market for the animal disinfectant market in Asia. Market growth in this region will be faster than the growth of the market in regions. The increasing prevalence of infectious diseases in animals will facilitate the animal disinfectant market growth in Asia over the forecast period Technavio has announced its latest market research report titled Animal Disinfectant Market by Type and Geography - Forecast and Analysis 2021-2025 Animal Disinfectant Market: Segmentation Analysis The animal disinfectant market report is segmented by Type (liquid animal disinfectant and powdered animal disinfectant) and Geography (Europe, North America, Asia, and ROW). Revenue generating segment: The animal disinfectant market share growth in the Liquid animal disinfectant segment will be significant for revenue generation. Liquid animal disinfectants are offered with the premixed dilution of concentrates (active ingredients) in the solvent (usually water). These products have higher adoption among end-users owing to their wide range of applications, including foot dips, footbaths, aerial disinfection, foam-based sprays, and water-system disinfection. For additional insights into the contribution of all the segments - Grab a sample report Animal Disinfectant Market: Key Market Dynamics Major Driver: An increasing prevalence of infectious diseases in animals is one of the key factors driving the growth of the global animal disinfectant market. The increasing prevalence of infectious diseases such as avian influenza, African swine fever, brucellosis, East Coast fever, African animal trypanosomiasis, Newcastle disease, porcine reproductive and respiratory syndrome (PRRS), and FMD has become a major concern among livestock farmers and governments across the globe. These diseases severely impact the livestock population by spreading like an epidemic with a high mortality rate. Moreover, a significant number of human diseases are zoonotic in origin and spread due to the direct or indirect contact of humans with the saliva, urine, blood, feces, mucous, or other body fluids of an infected animal. Advanced disinfectants have broad germicidal capabilities to remove such pathogens. Thus, to prevent infectious outbreaks, cleaning and disinfection processes using animal disinfectant products are gaining widespread adoption among animal care and animal breeding premises, which is driving the growth of the global animal disinfectant market Major Challenges: The stringent registration procedure is a major challenge for the global animal disinfectant market growth. Vendors manufacturing animal disinfectants operate in a highly regulated environment. A significant share of capital is invested by vendors in product R&D. However, as animal disinfectants involve the use of toxic chemicals, new formulations are subjected to strict testing trials and registration procedures for ensuring their safety. Failure in the performance and optimum safety standards may expose the products to the risk of rejection and discontinuation, thus causing significant financial loss to vendors. Furthermore, FIFRA mandates the disclosure and labeling of proper directions and safety precautions on the product. In addition to federal regulations, the US also has the presence of individual state-defined regulations. However, the disinfectant products that comply with these regulations can be commercialized in the EU countries. Similarly, in China, disinfectants are required to comply with the requirements of the Chinese Disinfectant Regulation. Vendors operating internationally often find it difficult to comply with the stringent and varying regulations across regions, which hampers their operational efficiencies and refrains the growth of the global animal disinfectant market. For additional details on the key drivers, trends, and challenges -. Request a Sample Report right now! Animal Disinfectant Market: Vendor Analysis The animal disinfectant market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market. CID LINES NV Diversey Inc. Evans Vanodine International Plc GEA Group Aktiengesellschaft KERSIA GROUP LANXESS AG Neogen Corp. Sanosil Ltd. Virox Technologies Inc. Zoetis Inc. To gain access to more vendor profiles with their key offerings available with Technavio, Click Here Get ready to achieve excellent business outcomes from this exclusive Animal Disinfectant Market report by Technavio. The report will include highlights of the overall market which includes frequently asked questions such as - What are historical revenue figures and estimated revenue figures as well as CAGR during the forecast timeframe? What is the current trend taking place in the market space? Which are business tactics that will influence competitive scenarios along with defining the growth potential of the market? What are market drivers, restraints, and challenges impacting demand & growth of the market? Which regions & segments will garner massive revenue and emerge as market leaders in upcoming years? The competitive scenario provided in the Animal Disinfectant Market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc.Don't wait, Make a strategic approach & boost your business goals with our Animal Disinfectant Market Forecast Report - Buy Now! Related Reports: The animal healthcare market share is expected to increase by USD 7.98 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 4.1%. The vaccine research market share is expected to increase to USD 13.34 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 8.36% Key Topics Covered: 1 Executive Summary 2 Market Landscape 2.1 Market ecosystem Exhibit 01: Parent market Exhibit 02: Market characteristics 2.2 Value chain analysis Exhibit 03: Value chain analysis: Life sciences tools and services 3 Market Sizing 3.1 Market definition Exhibit 04: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 05: Market segments 3.3 Market size 2020 3.4 Market outlook: Forecast for 2020 - 2025 Exhibit 06: Global - Market size and forecast 2020 - 2025 ($ million) Exhibit 07: Global market: Year-over-year growth 2020 - 2025 (%) 4 Five Forces Analysis 4.1 Five forces summary Exhibit 08: Five forces analysis 2020 & 2025 4.2 Bargaining power of buyers Exhibit 09: Bargaining power of buyers 4.3 Bargaining power of suppliers Exhibit 10: Bargaining power of suppliers 4.4 Threat of new entrants Exhibit 11: Threat of new entrants 4.5 Threat of substitutes Exhibit 12: Threat of substitutes 4.6 Threat of rivalry Exhibit 13: Threat of rivalry 4.7 Market condition Exhibit 14: Market condition - Five forces 2020 5 Market Segmentation by Type 5.1 Market segments Exhibit 15: Type - Market share 2020-2025 (%) 5.2 Comparison by Type Exhibit 16: Comparison by Type 5.3 Liquid animal disinfectant - Market size and forecast 2020-2025 Exhibit 17: Liquid animal disinfectant - Market size and forecast 2020-2025 ($ million) Exhibit 18: Liquid animal disinfectant - Year-over-year growth 2020-2025 (%) 5.4 Powdered animal disinfectant - Market size and forecast 2020-2025 Exhibit 19: Powdered animal disinfectant - Market size and forecast 2020-2025 ($ million) Exhibit 20: Powdered animal disinfectant - Year-over-year growth 2020-2025 (%) 5.5 Market opportunity by Type Exhibit 21: Market opportunity by Type 6 Customer landscape 7 Geographic Landscape 7.1 Geographic segmentation Exhibit 23: Market share by geography 2020-2025 (%) 7.2 Geographic comparison Exhibit 24: Geographic comparison 7.3 Europe - Market size and forecast 2020-2025 Exhibit 25: Europe - Market size and forecast 2020-2025 ($ million) Exhibit 26: Europe - Year-over-year growth 2020-2025 (%) 7.4 North America - Market size and forecast 2020-2025 Exhibit 27: North America - Market size and forecast 2020-2025 ($ million) Exhibit 28: North America - Year-over-year growth 2020-2025 (%) 7.5 Asia - Market size and forecast 2020-2025 Exhibit 29: Asia - Market size and forecast 2020-2025 ($ million) Exhibit 30: Asia - Year-over-year growth 2020-2025 (%) 7.6 ROW - Market size and forecast 2020-2025 Exhibit 31: ROW - Market size and forecast 2020-2025 ($ million) Exhibit 32: ROW - Year-over-year growth 2020-2025 (%) 7.7 Key leading countries Exhibit 33: Key leading countries 7.8 Market opportunity by geography Exhibit 34: Market opportunity by geography ($ million) 8 Drivers, Challenges, and Trends 8.1 Market drivers 8.2 Market challenges Exhibit 35: Impact of drivers and challenges 8.3 Market trends 9 Vendor Landscape 9.1 Overview 9.2 Vendor landscape Exhibit 36: Vendor landscape 9.3 Landscape disruption Exhibit 37: Landscape disruption Exhibit 38: Industry risks 10 Vendor Analysis 10.1 Vendors covered Exhibit 39: Vendors covered 10.2 Market positioning of vendors Exhibit 40: Market positioning of vendors 10.3 CID LINES NV Exhibit 41: CID LINES NV - Overview Exhibit 42: CID LINES NV - Product and service Exhibit 43: CID LINES NV - Key offerings 10.4 Diversey Inc. Exhibit 44: Diversey Inc. - Overview Exhibit 45: Diversey Inc. - Product and service Exhibit 46: Diversey Inc. - Key offerings 10.5 Evans Vanodine International Plc 10.6 GEA Group Aktiengesellschaft Exhibit 51: GEA Group Aktiengesellschaft - Overview Exhibit 52: GEA Group Aktiengesellschaft - Business segments Exhibit 53: GEA Group Aktiengesellschaft - Key news Exhibit 54: GEA Group Aktiengesellschaft - Key offerings Exhibit 55: GEA Group Aktiengesellschaft - Segment focus 10.7 KERSIA GROUP Exhibit 56: KERSIA GROUP - Overview Exhibit 57: KERSIA GROUP - Product and service Exhibit 58: KERSIA GROUP - Key news Exhibit 59: KERSIA GROUP - Key offerings 10.8 LANXESS AG Exhibit 60: LANXESS AG - Overview Exhibit 61: LANXESS AG - Business segments Exhibit 62: LANXESS AG - Key news Exhibit 63: LANXESS AG - Key offerings Exhibit 64: LANXESS AG - Segment focus 10.9 Neogen Corp. Exhibit 65: Neogen Corp. - Overview Exhibit 66: Neogen Corp. - Business segments Exhibit 67: Neogen Corp. - Key news Exhibit 68: Neogen Corp. - Key offerings Exhibit 69: Neogen Corp. - Segment focus 10.10 Sanosil Ltd. Exhibit 70: Sanosil Ltd. - Overview Exhibit 71: Sanosil Ltd. - Product and service Exhibit 72: Sanosil Ltd. - Key offerings 10.11 Virox Technologies Inc. Exhibit 73: Virox Technologies Inc. - Overview Exhibit 74: Virox Technologies Inc. - Product and service Exhibit 75: Virox Technologies Inc. - Key news Exhibit 76: Virox Technologies Inc. - Key offerings 10.12 Zoetis Inc. Exhibit 77: Zoetis Inc. - Overview Exhibit 78: Zoetis Inc. - Business segments Exhibit 79: Zoetis Inc. - Key news Exhibit 80: Zoetis Inc. - Key offerings Exhibit 81: Zoetis Inc. - Segment focus 11 Appendix 11.1 Scope of the report 11.2 Currency conversion rates for US$ Exhibit 82: Currency conversion rates for US$ 11.3 Research methodology Exhibit 83: Research Methodology Exhibit 84: Validation techniques employed for market sizing Exhibit 85: Information sources 11.4 List of abbreviations Exhibit 86: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email:[email protected] Website: SOURCE Technavio